title: Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection.
abstract: Guinea pigs were immunized with glycoprotein gD-2t in SAF-m or saline, then challenged with herpes simplex virus, type 2 (HSV-2). Animals given gD-2t in SAF-m had higher anti-gD-2t antibodies, fewer and less severe vaginal lesions, and decreased ganglionic latency compared to animals given gD-2t in saline. Leucocytes from animals vaccinated with gD-2t in SAF-m had greater proliferative responses to gD-2t in vitro than cells from control animals. MHC II-restricted, gD-2t-specific cytotoxic T cells were induced in guinea pigs vaccinated with gD-2t in SAF-m. Thus, immunization of guinea pigs with gD-2t in SAF-m markedly reduced the incidence and severity of primary HSV-2 by eliciting both humoral and cell-mediated responses.
authors.affiliation: Syntex Research, Palo Alto, CA 94304.
authors.forename: N E
authors.initials: NE
authors.lastname: Byars
authors.forename: E B
authors.initials: EB
authors.lastname: Fraser-Smith
authors.forename: R A
authors.initials: RA
authors.lastname: Pecyk
authors.forename: M
authors.initials: M
authors.lastname: Welch
authors.forename: G
authors.initials: G
authors.lastname: Nakano
authors.forename: R L
authors.initials: RL
authors.lastname: Burke
authors.forename: A R
authors.initials: AR
authors.lastname: Hayward
authors.forename: A C
authors.initials: AC
authors.lastname: Allison
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002455:Cell Division / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D005260:Female; D006168:Guinea Pigs; D006558:Herpes Genitalis / Q000517:prevention & control*; D006566:Herpesviridae Infections / Q000276:immunology / Q000517:prevention & control*; D018258:Herpesvirus 2, Human / Q000276:immunology; D007111:Immunity, Cellular; D008214:Lymphocytes / Q000276:immunology; D011136:Polysorbates / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000008:administration & dosage; D013185:Squalene / Q000008:administration & dosage / Q000031:analogs & derivatives; D014623:Vaginal Diseases / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D014759:Viral Envelope Proteins / Q000008:administration & dosage*
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D011136:Polysorbates; D011994:Recombinant Proteins; C077975:Syntex adjuvant formulation; D014759:Viral Envelope Proteins; C040570:glycoprotein D-herpes simplex virus type 2; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D013185:Squalene